The objectives ofthe Development Research Program of the DF/HCC Kidney Cancer SPORE are 1) to provide short-term funding for innovative and meritorious research projects in kidney cancer that have the potential to evolve into translational studies, 2) to fund efforts that will complement or enhance the overall scope and quality of the SPORE and 3) to ensure a confinual renewal of high quality and innovative translational research within the SPORE. These projects may be investigator-initiated laboratory or clinical research, or they may be designed to create a shared resource or enhance the research infrastructure of the SPORE. The Program will rely on the infrastructure created by the Administrafion, Evaluafion and Planning Core (Core 1) to accomplish these goals. The process will involve: 1) Identificafion of promising areas of translafional research related to kidney cancer 2) Solicitation of high quality applications addressing these and other areas 3) Selection of worthy projects for funding -Provision of critiques to selected projects -Provision of critiques, encouragement and support for potentially worthy, unselected projects 4) Provision of funds to the selected projects 5) Evaluation of progress and accomplishments ofthe projects including the possibility of 2nd year funding and transition into full project status 6) Evaluafion of the success of the Developmental Program as a whole This process has served us well in the initial SPORE funding period with four Projects in the current grant application (Projects 1, 3, 4 and 5) being based in total or in part on scientific knowledge that emerged from Developmental Projects. Results of the first funding cycle are summarized below. The specific steps in this process are described in more detail thereafter.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101942-08
Application #
8322747
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
8
Fiscal Year
2011
Total Cost
$128,245
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Zhang, Jinfang; Bu, Xia; Wang, Haizhen et al. (2018) Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553:91-95
Gao, Xin; Jegede, Opeyemi; Gray, Connor et al. (2018) Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer 16:341-348
Liu, Wenjing; Chen, Binbin; Wang, Yang et al. (2018) RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism. Proc Natl Acad Sci U S A 115:E1475-E1484
Iorgulescu, J Bryan; Braun, David; Oliveira, Giacomo et al. (2018) Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med 10:87
Gopal, Raj K; Kübler, Kirsten; Calvo, Sarah E et al. (2018) Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell 34:242-255.e5
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Signoretti, Sabina; Flaifel, Abdallah; Chen, Ying-Bei et al. (2018) Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol :JCO2018792259
Hamieh, Lana; Choueiri, Toni K; Ogórek, Barbara et al. (2018) Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet 14:e1007679
Gao, Xin; McDermott, David F (2018) Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. Expert Opin Biol Ther 18:947-957
Gopal, Raj K; Calvo, Sarah E; Shih, Angela R et al. (2018) Early loss of mitochondrial complex I and rewiring of glutathione metabolism in renal oncocytoma. Proc Natl Acad Sci U S A 115:E6283-E6290

Showing the most recent 10 out of 153 publications